The Sequencing Thesis
Most enterprises fail at AI.
Not because the models are wrong.
Because the sequence is wrong.
B·E·A·T and the 5Ps are practitioner frameworks for enterprise leaders moving AI from pilot to compounding advantage. Together they answer the two questions every AI transformation must answer — on two different planes.
60%
of AI projects lacking AI-ready data are abandoned before delivering value [1]
10–15%
of commercial technology investments measurably move business KPIs [1]
2×
revenue growth for highest maturity vs. average peers [6]
Upcoming
Full schedule →
Scroll
The Sequencing Thesis
Distinct planes. Continuous transformation.
The two frameworks are never separate — they cross wherever real transformation happens.
B·E·A·T
Stack sequencing
BBuild
EEnable
AAccelerate
TTransform
THE 5Ps
Capability sequencing
P1POC
P2Pilot
P3Product
P4Platform
P5Performance
Two loops that never separate. B·E·A·T flows through the enterprise stack. The 5Ps flows through each AI capability. Wherever real transformation happens, they cross.
Interactive diagram
Click any framework label to explore
← B·E·A·T
The Sequencing Thesis (center)
The 5Ps →
Who this is for
Which sequencing question are you trying to answer?
Three enterprise roles arrive here for three different reasons. Find yours — then start where it matters.
Enterprise Technology Leader
CIO · CDO · CTO
Your pain
You're deciding what to build first — because AI can't work on the wrong foundations. Your teams keep asking for AI budget. Your data isn't ready. The board wants results yesterday.
You need to know
- Which foundational investments to make first, and in what order
- How your current stack maturity constrains what AI you can actually deploy
- Where to gate AI initiatives against readiness, not calendar
Start with B·E·A·T — the stack sequencing framework
→
AI & Product Leader at Scale
VP Product · Head of AI · ML Product Lead
Your pain
You've shipped pilots. Now leadership wants scale — and the old playbook won't get you there. Every capability stalls at Product or Platform. You need to know which stage gate your team keeps skipping.
You need to know
- How AI capabilities actually mature from POC into compounding outcomes
- Which quality gates every stage transition must pass
- What the fifth stage — Performance — requires structurally
Start with the 5Ps — the capability sequencing framework
→
Transformation Leader
Chief Transformation Officer · COO · SVP Strategy
Your pain
You're accountable for outcomes but the tools aren't delivering. You need to know whether the problem is your foundations or your ambition — and which sequence unlocks the compounding you promised.
You need to know
- Where your organization sits across both sequencing planes right now
- Which quadrant of investment posture matches your reality
- What sequence unlocks measurable outcomes vs. more pilot theater
Take the 30-second sequencing diagnostic
→
Frameworks & diagnostics on this site are free to use with attribution. Personal practitioner perspective — independent of any employer.
The two frameworks
Two frameworks. Two planes. One transformation.
B·E·A·T sequences the enterprise stack. The 5Ps sequences the AI capability. Every enterprise AI transformation must answer both.
Framework 1 · Stack sequencing
B·E·A·T
The four load-bearing tiers of the enterprise commercial technology stack — sequenced so AI capabilities can actually work.
B
Build
›
E
Enable
›
A
Accelerate
›
T
Transform
Answers
"What do we invest in first?" Where the operational floor lives. Which tier gates the next. Where AI can vs. cannot work today.
Read the framework →
Framework 2 · Capability sequencing
The 5Ps
The five stages every AI capability must climb from experiment to compounding outcome. The fifth — Performance — is where the business actually changes.
P1
POC
›
P2
Pilot
›
P3
Product
›
P4
Platform
›
P5
Performance
Answers
"How does each capability mature?" Which stage every AI initiative sits at. What each transition gate requires. Where compounding advantage lives.
Read the framework →
Introducing B·E·A·T
From Operate to Transform
The decision system for what to build next — and in what order.
A sequencing model for enterprise commercial technology investment. Four load-bearing tiers. One non-negotiable order. Built in pharma, applicable beyond it — because the physics of stack maturity apply everywhere AI touches operating systems.
10–15%
of commercial tech investments measurably move business KPIs [1]
60%
of AI projects lacking AI-ready data are abandoned before delivering value [1]
2×
revenue growth for highest omnichannel maturity vs. average peers [6]
Billions
in annual pharma SG&A spend — the problem is sequence, not investment [21]
B
Build to Operate
CRM · Hub · Claims · HCP identity · Field workflows. The operational floor: without this, nothing downstream is real.
The floor question
E
Enable
MDM · CDP · Omnichannel · Identity · Consent. The decision-quality layer: whether the data can be trusted to drive judgment.
The trust question
A
Accelerate
NBA engine · AI field chat · PA automation · Routing. The revenue tier: where AI touches the actual commercial workflow.
The revenue question
T
Transform
Agentic PA · Autonomous decisions · AI commercial model. Not automation — a rewrite of the operating model.
The operating-model question
Introducing the 5Ps
From Experiment to Performance
Five stages every AI capability must climb — and the graduation rules between them.
The 5Ps of Outcomes-Driven AI Transformation. Where B·E·A·T answers what to build first at the enterprise stack level, the 5Ps answers how every capability matures from experiment into compounding advantage. Skip a stage gate and the capability stalls — usually visibly, sometimes silently.
P1
POC
The learning stage. A demonstration that the technology can produce the intended output under narrow conditions. Not a product.
The feasibility question
P2
Pilot
Controlled deployment with real users. Tests whether the capability survives contact with actual workflow, edge cases, and human judgment.
The survival question
P3
Product
Reliable capability with defined SLAs, accountability, and quality gates. Most enterprises stall here — and don't realize it for 18 months.
The reliability question
P4
Platform
Shared infrastructure that reduces marginal cost of the next capability. Real platforms compound; costume platforms don't.
The compounding question
P5
Performance
The rare stage: AI outcomes generate closed-loop signal that improves the models that generate more outcomes. Compounding business advantage.
The outcomes question
Why B·E·A·T
The framework pharma commercial
organizations actually need
Not another technology playbook. A sequencing model built from real decisions — on which capabilities to build, in what order, and why skipping any tier creates compounding costs downstream.
For Commercial Technology Leaders
Answer the question every SVP asks
"Are we investing in the right tier — or the tier we wish we were in?" B·E·A·T gives you a structured answer with gates that protect every dollar above them.
Use the Decision Tool →
For AI and Digital Strategy
60% of AI projects lacking AI-ready data will be abandoned before they deliver value. [1] Here is why.
Not because of the AI. Because Enable was skipped. A Next-Best-Action engine deployed on un-mastered HCP identity makes confident wrong recommendations. The sequence is structural.
See AI at Scale →
For Executive Stakeholders
Transform is a state you earn, not announce
Agentic workflows, autonomous PA, self-optimizing omnichannel — all require B, E, and A to be production-stable first. Three real scenarios show exactly how it works in practice.
See Use Cases →
SG
Personal Perspective — Author Disclaimer
The views expressed are those of Saurav Gupta personally and do not represent any employer, client, or affiliated organization. This framework is original practitioner work. © 2026 Saurav Gupta.
01 — The Problem
The technology worked.
The foundation didn’t.
A sequencing problem. Not an investment problem.
Pharma commercial organizations have spent billions on digital over the past five years. The outcomes have been uneven — not because the tools failed, but because the foundation underneath them was never stable enough to carry the weight.
A Next-Best-Action (NBA) engine deployed on un-mastered prescriber data generates recommendations the field can’t act on. A patient access platform built without a live claims feed leaves hub operations flying blind. A generative AI tool writes for HCPs (Healthcare Providers) who changed practice settings eight months ago. In every case, the technology worked. The foundation didn’t. [1, 2, 8]
The problem is not investment. Large pharma companies spend an average of 25–40% of revenue on SG&A — which includes all commercial operations, technology, and field force costs [21]. The problem is not investment. The problem is sequence. Organizations invest in the tier they wish they were in, not the tier they’re actually in. They fund Accelerate without having built stable Enable. They announce Transform without having proven Accelerate. And when it fails, they call it an AI problem. It was always a sequencing problem. [3, 19]
The B·E·A·T Framework
“Skip a step and you don’t just fall behind — you EAT the cost of rebuilding. The sequence is structural. Every tier carries the weight of what sits above it.”
Build Failure
CRM (Customer Relationship Management) data degrades. HCP affiliation accuracy degrades materially without active MDM (Master Data Management) governance. Every AI model above inherits the rot. [6]
Enable Skipped — Field Force Pays the Price
Stale CRM data. No MDM. NBA routes the rep to a practice the physician left two quarters ago. An NBA system that requires mastered identity to achieve its 30–40% engagement lift will produce the opposite on fragmented data. [28] The Reimbursement Specialist gets a case with the wrong payer ID. The Medical Liaison schedules an exchange at the wrong institution. One data failure. Three field roles flying blind. [6, 9]
Accelerate Before Gates
Patient access platform launches without live claims feed. Hub operations blind. Time-to-first-fill degrades. Field loses confidence in platform within 60 days. [7]
02 — The Framework
B·E·A·T — Four tiers. One sequence.
Each tier is load-bearing for the next. Build is the floor. Enable is the ceiling on every decision above it. Accelerate is where technology starts moving commercial outcomes. Transform is the model reinvention that only works when the other three are stable.
Strategic Maturity
Model reinvention
Revenue impact
Decision quality
Commercial reliability
Sequence is structural — every tier carries the weight of what sits above it · Click any tier to expand
B · Build · Now & Always
Commercial Operations Floor
The systems and data flows that keep commercial operations running reliably and compliantly. Every investment above depends on this being stable.
CRM · Hub enrollment · Claims feeds · HCP/HCO identity · Reimbursement Specialist workflows · Patient consent · Call planning data
KPI: CRM completion rate · Hub SLA · Claims latency · Reimbursement Specialist case volume · Medical Liaison call quality
If Build is unstable
CRM data degrades materially without active MDM governance — HCP affiliation accuracy erodes silently over months. Every AI model above inherits the rot. NBA routes field teams to wrong practices. Reimbursement Specialist cases file against wrong payer IDs. The foundation rots silently — until the AI announces it loudly. [6, 8]
E · Enable · Intelligence Layer
Decision Quality Ceiling
Raises the ceiling on every downstream decision. Without mastered identity and unified signal, AI recommendations are confidently wrong. [23, 1]
MDM · CDP (Customer Data Platform) · Omnichannel backbone · Consent architecture · Insights infrastructure
KPI: HCP match rate · Channel coherence score · Data freshness index
If Enable is skipped
The same prescriber commonly exists as separate records across multiple commercial systems with no master record. NBA deploys on fragmented identity — generating recommendations the field cannot act on. AI chat briefs reps on physicians who moved practice settings. NBA platform investment written off at 6-month review. [9]
A · Accelerate · Revenue Tier
Commercial Outcomes Engine
Where technology begins directly moving commercial outcomes. PA (Prior Authorization) automation reduces time-to-therapy 42–58%. AI copilots cut field admin 25–30%. AI-driven dynamic targeting routes the right rep, Medical Liaison, or Reimbursement Specialist at the right moment. [13, 14]
NBA (Next-Best-Action) engine · Dynamic targeting & routing · AI field chat · PA automation · Reimbursement Specialist automation · Outcomes Liaison outcomes tracking
KPI: TRx (Total Prescriptions) lift · Time-to-therapy · PA deflection rate · Reimbursement Specialist case resolution · Outcomes Liaison engagement quality
If Accelerate is mis-gated
T · Transform · Model Shift
Operating Model Reinvention
Not process efficiency — commercial model reinvention. Agentic workflows, autonomous PA, self-optimizing omnichannel. Only works when B·E·A are production-stable. [2, 18]
Agentic PA · Dynamic territory AI · Autonomous formulary response · Self-optimizing omnichannel · AI commercial model
KPI: Decisions automated · Cost per patient · Hub case deflection rate
If Transform is announced before B·E·A are earned
Board approves agentic AI roadmap for Year 1. Build not stable. Enable not mastered. Agent deploys into an environment it can’t trust. It fires on ghost approvals. MLR (Medical, Legal, Regulatory) review finds no audit trail. Program suspended indefinitely. [15]
Without Sequence
The technology
worked. The
foundation didn’t.
✗ Without B·E·A·T Sequence
NBA deployed on 14-month-old HCP data. Targeting accuracy compromised from day one.
Same prescriber exists across multiple disconnected systems. AI recommendations built on fragmented identity are confidently wrong.
PA automation fires without live claims feed. Time-to-first-fill remains above 18 days. Siloed hub systems mean Reimbursement Specialists lack visibility into patient journey data. [13, 33]
Rep, Medical Liaison, Reimbursement Specialist, and Outcomes Liaison working from four separate systems. No shared account view.
Agentic AI deployed. Claims feed unreliable. Agent fires on ghost approvals.
Leadership calls it an AI problem. It was always a sequencing problem.
With Sequence
The sequence
is structural.
Every tier loads the next.
✓ With B·E·A·T Sequence
NBA gated on MDM match rate ≥82%. Rep targeting grounded in clean, mastered HCP identity. [15]
Single mastered prescriber identity. AI recommendations grounded in clean signal.
PA automation on live claims. Time-to-first-fill drops from an 18-day average to under 10 days. [13]
AI dynamic routing sends the right person to the right account. One shared view.
Agentic PA on production-stable B·E·A. PA processing time compressed materially with automation. [16, 18]
Organizations with the highest omnichannel maturity show 2× the revenue growth of average omnichannel maturity peers [6].
“The difference is not the technology. It is the order in which it is built.”
03 — How to Prioritize
Score your B·E·A·T — then BET on the right sequence
Know where you EAT risk · and where you AT scale
Criterion
Score 1
Score 3
Org scale
Portfolio breadth and resourcing capacity
Small
Large
Speed pressure
Launch window or competitive urgency
Urgent
Low
Tech maturity
CRM, claims, MDM stability today
Low
High
Capital runway
Budget and brand lifecycle stage
Tight
Full
Change capacity
Field and ops adoption bandwidth
Low
High
Compliance burden
GxP, HIPAA, MLR cycle speed
Heavy
Light
Q1 · Build Deep
All tiers concurrent
All tiers concurrent. Build, Enable, Accelerate mature. Transform pilots viable now.
B
E
A
T
15–18Q2 · Accelerate Now
Aggressive parallel: B+E+A
Aggressive parallel. Build, Enable, and Accelerate run together. Transform scoped for Year 2.
B
E
A
T
12–15Q3 · Build First
Selective parallel: B+E
Selective parallel. Build and Enable run together. Accelerate after both gates pass. A & T are Year 2.
B
E
A
T
9–12Q4 · Triage & Compress
Sequential only: B then E
Sequential only. Build stabilizes before Enable begins. MVP B for launch. Transform deferred until post-launch.
B
E
A
T
6–9↑ High MaturityHigh Urgency →
04 — The Customers You’re Building For
Four stakeholders. Four gaps.
One sequence closes all of them.
Click Today / 2030 on each card to toggle between the current state and the future state that B·E·A·T enables. [5, 6]
HCPSpecialist · High-volume prescriber
From fragmented noise → to one coherent signal
4–6 rep visits/week with duplicated information. Three reps from the same company present conflicting formulary data in the same month. Digital sends emails she didn’t opt into. [11]
E MDM → A NBA → T Omnichannel coherence
PatientSpecialty · Hub enrollment
From 18-day wait → to access that resolves itself [13]
Approved for a biologic Tuesday. Calls hub four days later, told to call back. Prior authorization pending 18 days on average without technology-enabled automation. An estimated 3 out of 4 specialty brand patients fail to fill a new prescription due to payer controls. [20] [13] PA delays range from days to weeks without hub integration; e-enrollment reduces time to therapy by up to 4 days. [33] First fill never happens. Over 90% of physicians report patient care delays due to prior authorization complexity — the primary barrier in specialty access. [17] [5, 7]
B Hub ops → E Claims CDP → A PA automation → T Agentic
Field TeamRep · Medical Liaison · Reimbursement Specialist · Outcomes Liaison
From siloed roles, fragmented data → to one coordinated signal
The rep, Medical Liaison, Reimbursement Specialist, and Outcomes Liaison each work from different systems with no shared account view. The rep calls on the prescriber Tuesday. The Medical Liaison schedules a scientific exchange Thursday — neither knows the other was there. [6, 14]
AI-driven dynamic targeting routes the right person — rep, Medical Liaison, Reimbursement Specialist, or Outcomes Liaison — to the right account based on current signal. An AI chat interface surfaces account context at point of call. All from one mastered HCP/HCO identity. PA processing time reduced 30%+ with AI automation. [16]
B CRM/Field mgmt → E MDM + HCO hierarchy → A Dynamic routing + AI chat → T Coordinated field AI
PayerPharmacy director · IDN · PBM
From quarterly lag → to real-time outcomes intelligence
Formulary proposals arrive without real-world outcomes data she can verify. The Reimbursement Specialist calls quarterly with pull-through reports the payer can’t reconcile. Coverage change decisions happen without manufacturer awareness — the field finds out from a rejected PA. [5, 10]
Real-time formulary pull-through mapped to her own claims. The Reimbursement Specialist arrives with verified outcomes data. Coverage changes trigger manufacturer alerts within hours. ows which accounts warrant investment ahead of renewal windows. Every downstream system knows what she does. [5, 10]
B·E·A·T posture: Build · Enable · Accelerate
05 — Use Cases
B·E·A·T in practice
Three real pharma commercial scenarios. Each shows exactly how sequencing applies — and what breaks when a tier is skipped.
01
Specialty Launch
Year 1 go-live with compressed timeline. How to sequence CRM, MDM, and NBA when leadership wants AI at launch.
B active · E compress →
02
CRM Consolidation
Three legacy CRMs from acquisitions. How to run parallel B+E tracks while maintaining field continuity.
Parallel B+E · High maturity →
03
Agentic Patient Services
Full Transform ambition. Autonomous PA, agentic patient support — only possible because B·E·A were earned first.
Transform active · All tiers →
01
Specialty Brand Launch — Year 1 Go-Live
B activeE compressUrgent · Low maturity
▶ Executive Takeaway
Ship Build first, even if it delays launch by weeks. Industry evidence shows that fragmented commercial data at launch leads to slower script uptake and field credibility loss — consequences that outlast the delay. [24]
► THE SITUATION
Launch in 12 months. CRM last refreshed 18 months ago. Hub onboarding manual — averaging 18 days without automation [13]. No MDM. NBA vendor already contracted. Leadership wants AI copilot at launch. Industry evidence shows 89% of biopharma AI pilots fail to scale, with data fragmentation as the primary cause. [24]
THE B·E·A·T SEQUENCE
B
BUILD
M1–M4
Emergency CRM refresh. NPI hierarchy corrected. Hub workflow digitized. Claims feed connected. Data quality baseline established before any AI investment.
Gate: CRM completion ≥90%
96% of pharma leaders say data is not AI-ready for scaling pilots. Build solves this first. [24]
E
ENABLE
M3–M7
MVP MDM layer. Single prescriber identity. CDP ingesting enrollment and claims. Consent architecture production-grade.
Gate: MDM match rate ≥82%
A
ACCELERATE
M8 (launch)
NBA go-live gated on MDM match rate — NOT the launch date. AI copilot activated. PA automation live on clean claims feed. Dynamic HCP targeting active.
Gate: match rate, not calendar
T
TRANSFORM
Year 2+ (scoped)
Agentic PA piloted after Accelerate proves stable at scale. Score of 7 does not support Transform now.
Deferred explicitly
▶ WHAT BREAKS IF A DEPLOYS BEFORE E REACHES ≥85%?
NBA launches on stale HCP data. Field receives recommendations they cannot act on. Trust erodes within weeks. [24]
AI copilot briefs reps on HCPs who moved practice settings. Credibility cost outlasts technology cost. [1, 2]
RESULT
02
Mature Multi-Brand Portfolio — CRM Consolidation & MDM Build
All tiers activeParallel B+ELow urgency · High maturity
▶ Executive Takeaway
High maturity earns parallel tracks. But E still gates A. The MDM match rate is the difference between AI that works and AI that routes confidently wrong. A unified HCP identity is what makes every downstream model trustworthy. [23], [24]
► THE SITUATION
Three legacy CRM systems from three acquisitions. No single HCP identity. MDM project stalled 2 years. 72% of companies spend up to 100 days annually reconciling HCP data across sources — a pattern directly documented across pharma commercial technology implementations. [24] Leadership wants AI-driven territory optimization by Q3.
THE B·E·A·T SEQUENCE
B
BUILD
Stream 1 · M1–M6
CRM consolidation. Single rep activity record. Claims normalized. Parallel track — does not wait for E.
Parallel with Enable
E
ENABLE
Stream 2 · M1–M8
MDM build. Single prescriber master. CDP integrates CRM, claims, and digital. Consent architecture embedded.
Gate: ≥85% match rate
A
ACCELERATE
M9–M14
NBA + AI dynamic targeting routes rep, Medical Liaison, and Reimbursement Specialist by signal. AI chat at point of call. Omnichannel NBA drives 15–40% increase in HCP engagement when built on mastered identity. Data-driven targeting significantly improves field effectiveness and engagement outcomes. [16, 28, 29]
Unlocks after E gate
T
TRANSFORM
Year 2
Dynamic territory reallocation by AI in-week. Reimbursement Specialist cases auto-routed. Outcomes Liaison outcomes mapped to payer cohorts in real time.
After A proves lift
03
Large Pharma — Agentic Patient Services at Scale
Transform activeLow urgency · High maturity
▶ Executive Takeaway
Transform is not a destination you announce. It is a state you earn — tier by tier. The agentic PA program works because every upstream dependency was already production-stable. B·E·A earned this.
► THE SITUATION
B and E are stable. NBA is live on a mastered HCP identity layer. PA automation is reducing processing time by 30%+ vs. manual workflows. [16] Board has approved agentic patient services: autonomous PA drafting, submission, and appeal — enabled by production-stable Build and Enable tiers. Only 11% of companies reach this level of value realization. [25]
THE B·E·A·T SEQUENCE
B
BUILD
E
ENABLE
Stable · gates passed
Unified identity live. Consent architecture production-grade. Closed-loop signal returning outcomes. MLR-auditable data lineage embedded.
✓ Gates passed
A
ACCELERATE
Active · optimizing
NBA live on mastered identity. PA automation reducing processing time 30%+ vs. manual. [16] EY documents that end-to-end PA digitization requires integrated claims data and unified patient identity as the foundation. [32] Closed-loop signal feeds back to models weekly. [Ref. 3, 14, 15]
✓ Lift proven
T
TRANSFORM
Year 2
Agentic PA: autonomous drafting, submission, appeal, routes to hub — no human initiates. MLR-embedded reasoning. Compliance audit trail native to every agent action. Agentic AI requires production-stable foundations; automation amplifies errors at scale when data architecture is not ready. [34]
Earned — piloting now
▶ WHAT IF TRANSFORM LAUNCHED BEFORE A WAS PROVEN?
Claims feed not production-grade. Agent fires on stale approvals. Patients receive submissions for plans that already denied.
MLR has no audit trail for agent reasoning. First denied appeal triggers regulatory review. Program suspended indefinitely. Agentic AI without data maturity amplifies errors at commercial scale rather than reducing them. [1, 2, 34]
Board withdraws agentic AI investment across all programs — not just patient services. Credibility cost outlasts technology cost by years. 70% of digital transformations that skip sequencing fail to achieve their objectives; only 30% of transformations succeed in achieving their objectives and creating sustainable change. [26, 27]
RESULT
0
PA cases by field rep
fully autonomous
Only possible because B·E·A were earned first. Every tier below this one was load-bearing. The 11% of companies that reach scaled AI value share this pattern: they built the foundation before deploying the intelligence. EY confirms that PA automation at scale requires end-to-end integration and a digital operating model — not just technology. [Ref. 15, 18, 25, 32]
06 — AI at Scale
Enabling B·E·A·T for AI-first commercial delivery
Don’t skip a BEAT · EAT the data problem first · AT the frontier only when earned
What this section is about · AI Usage Readiness
This section is about AI usage readiness — the commercial technology substrate that determines whether your enterprise can meaningfully use AI at all. Modular architecture. Mastered identity. Closed-loop signal. The infrastructure any AI capability has to sit on.
Being ready to use AI is not the same as being ready to transform with AI. Usage readiness is a stack question. Transformation readiness is a capability progression question — how each AI capability moves from experiment to compounding business outcome. Different plane, different framework. We'll bridge to that at the end of this section.
The gap the four stakeholders revealed
Every stakeholder on the Customers page has a 2030 expectation that requires AI to deliver it. The HCP’s coherent signal requires a mastered identity layer. The patient’s self-resolving access journey requires agentic PA. The field team’s AI-briefed calls require a closed-loop signal. The payer’s real-time intelligence requires autonomous formulary response. None of these are AI problems. They are all sequencing problems. The organizations that reach these outcomes will have earned them — tier by tier. [3, 4, 19, 27]
LAYER ↓
SEQUENCE →
SEQUENCE →
B
E
Don’t skip a Beat
Foundational
E
A
T
EAT the data problem
Intelligence
A
T
AT the frontier
Transformation
INFRA &
DATA
DATA
Modular, API-first design
Monolithic platforms create sequencing debt. Each capability — CRM, hub, claims, MDM, NBA — must be independently upgradeable. Build this from day one or pay to rebuild at every tier transition. [19]
Unified Commercial Identity
The AI-first model breaks wherever the same person has a different identity in different systems. A single, persistent, consent-aware identity across CRM, hub, claims, digital, and medical is the prerequisite for everything above it. The same HCP commonly exists as separate records across CRM, hub, claims, digital, and medical affairs systems — without a single mastered identity. [9]
INTEL &
DECISIONS
DECISIONS
AI-Ready Data Governance
Build the Environment, Then the Agent
Governance Embedded in Compliance Review
Build · Now
Enable · M3–M8
Accelerate · M8–M18
Different question, different framework · AI Transformation Readiness
Being ready to use AI is not the same as being ready to transform with it.
Everything above answers can your stack support AI at all? Modular architecture, mastered identity, closed-loop signal, agentic-ready workflows — the substrate. That's AI usage readiness.
The next question is entirely different: once you can use AI, how does any single AI capability progress from experiment to compounding business outcome? That's AI transformation readiness — a capability sequencing problem, not a stack sequencing one. Different plane. Different failure modes. Different framework.
The 5Ps of Outcomes-Driven AI Transformation — POC → Pilot → Product → Platform → Performance — answers the transformation question. B·E·A·T gets you to capability. The 5Ps takes that capability to compounding advantage.
07 — The Practitioner Guide
Don’t skip a BEAT — or you’ll AT the wrong tier
This is a gate system, not a checklist. Each gate must be passed before the next tier unlocks. [3, 19]
The Five Practitioner Gates
1
Build gate — Data integrity audit
Before any Enable investment, run a full CRM data quality audit. NPI (National Provider Identifier) hierarchy accuracy must exceed 85%. Claims feed latency must be under 24 hours. Hub enrollment SLA (Service Level Agreement) must be documented. If not met, no Enable investment should be approved. [6, 12]
B is the floor. You don’t lay carpet before you pour concrete.
2
Enable gate — Master data match rate
MDM match rate must reach ≥85% before NBA go-live — not at the launch date, not on the project plan date. The Accelerate tier is gated on Enable quality. This is the most commonly skipped gate in pharma commercial. It is why 60% of AI projects lacking AI-ready data will be abandoned before they deliver value. [1]
EAT the data problem before it eats your AI investment.
3
Accelerate gate — Outcomes before scale
Prove measurable commercial lift before scaling any Accelerate investment. NBA must show attributable TRx (Total Prescriptions) lift in a pilot cohort before fleet-wide deployment. PA automation must hit time-to-therapy targets in a region before national rollout. [12, 13]
Accelerate means accelerate outcomes, not accelerate spend.
4
Transform gate — B·E·A production stability
Before any agentic AI deployment, confirm all three prior tiers are production-stable. Live claims feeds with documented SLA, mastered identity with ≥85% match rate, and closed-loop signal architecture returning outcomes. [15, 8]
AT the frontier only after BEA are earned.
The Most Common Sequencing Mistakes
Investing at the tier you wish you were in
Approving NBA vendor contracts before MDM exists. Announcing Transform strategy before Accelerate has proven lift. Budget follows ambition, not maturity. The result: 60% of AI projects lacking AI-ready data are abandoned before delivery. [1]
Treating Build as solved after initial deployment
Setting Transform timelines before gates are passed
Board approves agentic AI roadmap for Year 1. Build is not stable. Enable is not mastered. The agent deploys into an environment it can’t trust. Credibility cost outlasts technology cost by years. [15]
Using launch date as the Accelerate gate
Three Questions for Every Investment Decision
1. Which B·E·A·T tier does this investment belong to — and is that tier’s gate already passed?
2. Which of the four stakeholders (HCP, patient, field team, payer) does this directly serve — and how?
3. What commercial metric does this move, and by when? If you can’t answer this, it belongs in the backlog — not the roadmap.
Interactive Decision Tool
Score your organization.
See your B·E·A·T posture instantly.
Get your B·E·A·T posture in 2 minutes
Drag each slider to score 1–3. Your total maps to one of four investment quadrants — with specific sequence, watchouts, and AI readiness guidance.
B·E·A·T Criteria
12
/18
Org scale2
Portfolio breadth and resourcing capacity
1 · Small3 · Large
Speed pressure2
Launch window or competitive urgency
1 · Urgent3 · Low urgency
Tech maturity2
CRM, claims, MDM stability today
1 · Low3 · High
Capital runway2
Budget and brand lifecycle stage
1 · Tight3 · Full
Change capacity2
Field and ops adoption bandwidth
1 · Low3 · High
Compliance burden2
GxP, HIPAA, MLR (Medical-Legal-Regulatory) cycle speed
1 · Heavy3 · Light
AI Investment Appetite
AI ambition level2
Where is leadership currently pushing to invest?
1 · Foundation (B/E)3 · Transform
Q
Move sliders to see your posture
Adjust all 7 sliders above
—
Total /18
—
Urgency
—
Maturity
Investment Posture Matrix
↑ HIGHER MATURITY · HIGHER SCORE
Technology
Maturity
Maturity
Q1 · BUILD DEEP
All tiers concurrent
Score 15–18
Q2 · ACCELERATE NOW
Aggressive parallel: B+E+A
Score 12–15
Q3 · BUILD FIRST
Selective parallel: B+E
Score 9–12
Q4 · TRIAGE & COMPRESS
Sequential only: B then E
Score 6–9
← Lower Urgency
Higher Urgency →
Low
Move sliders to see your posture
Adjust the sliders → your B·E·A·T posture appears here
Apply B·E·A·T to Your Organization
Apply B·E·A·T — know exactly what to build next.
Align strategy, data, and execution in one decision system.
Use the Decision Tool above to find your quadrant. Start with your gates. Build the tier you are actually in — not the one you wish you were in.
Application & Scope
Built in pharma.
Applicable everywhere.
The B·E·A·T Framework was forged in pharmaceutical commercial technology — one of the most complex, regulated, and data-intensive commercial environments in the world. But the sequencing problem it solves is not unique to pharma. Anywhere AI is deployed on top of fragmented data, the same failure pattern emerges.
Within Pharma Technology
Commercial Technology
CRM · Hub enrollment · HCP identity · NBA engines · Patient services · PA automation · Omnichannel engagement
Where B·E·A·T was developed and battle-tested
Medical Affairs Technology
Medical Liaison platforms · KOL identity · Evidence dissemination · Scientific exchange tracking · Outcomes Liaison analytics
Same sequence: identity before engagement, engagement before AI
Market Access & Payer Tech
Payer master data · Formulary tracking · Contract analytics · Real-world evidence · Value demonstration platforms
Fragmented payer identity = broken access strategy
R&D & Clinical Technology
Clinical trial data · Site master data · Patient registries · Regulatory submissions · Pharmacovigilance systems
Data integrity is patient safety. Build first, always.
Supply Chain & Manufacturing
Serialization · Cold chain tracking · Demand forecasting · Plant-level ERP integration · Quality systems
Operational reliability (Build) before predictive optimization
Beyond Pharma — The Same Pattern Everywhere
Financial Services
Client identity fragmented across wealth, retail, and institutional desks. AI personalization deployed before a golden client record exists. The model routes recommendations to the wrong account.
B·E·A·T fix: Client MDM before AI advisor
Healthcare Systems & Payers
Patient records fragmented across EHRs, claims, and care management. Predictive readmission models trained on incomplete data. Clinical AI makes confident wrong recommendations.
B·E·A·T fix: Patient identity before clinical AI
Retail & Consumer Goods
Customer data siloed across e-commerce, in-store, loyalty, and wholesale. Personalization engine recommends products the customer already returned. Same sequencing failure. Different industry.
B·E·A·T fix: Unified customer identity before NBA
MedTech & Industrial
Device serial numbers not reliably linked to accounts, service records, or patient outcomes. Predictive maintenance models trained on fragmented asset data. AI predicts failure — in the wrong device.
B·E·A·T fix: Asset master before predictive ops
The Universal Pattern
AI fails not because the model is wrong. It fails because the data underneath it was never ready to carry the weight.
This is the sequencing problem. Every organization that has deployed AI on top of fragmented identity, disconnected systems, or unmastered data has paid the same credibility cost. B·E·A·T names the pattern, gates the tiers, and gives technology leaders a decision framework that works regardless of therapeutic area, business unit, or industry vertical.
Intellectual Property & Copyright
The B·E·A·T Framework — including its sequencing model, tier definitions, gate system, decision tool, use case methodology, and all associated original content — is the intellectual property of Saurav Gupta. © 2026 Saurav Gupta. All rights reserved.
Permitted Use
Non-commercial professional discussion and citation with attribution is permitted. Commercial use, reproduction, training of AI systems on this framework, or adaptation without written permission is prohibited. Framework is applicable across industries and technology functions — original authorship must be preserved in any application or reference.
— Practitioner Thoughts
Frameworks, articles & field notes
Original thinking on moving enterprise AI from isolated experiments to production capability that scales — written from the field, not the sidelines.
Author · Practitioner
Saurav (Rav) Gupta
Also publishes as “Rav Gupta” on Medium & LinkedIn
Enterprise AI Product & Platform Transformation Leader
“Most organizations don’t struggle to build AI. They struggle to scale it.”
Helping leaders move AI from isolated experiments to enterprise capability that creates measurable, sustainable business impact — through product thinking, platform strategy, and operating-model design. 18+ years across pharma, healthcare, MedTech & financial services.
Two frameworks · One transformation
B·E·A·T sequences the enterprise. The 5Ps sequences the AI capability.
Enterprises don't fail at AI. They fail at sequencing — and they fail at it on two different planes at once. B·E·A·T answers where to invest first in the commercial technology stack so the enterprise is structurally ready. The 5Ps of Outcomes-Driven AI Transformation answers how each AI capability progresses from experiment to compounding advantage. You can run POCs on shaky B·E·A·T foundations. You cannot reach Performance without them.
Featured · Stack SequencingOn this site
B·E·A·T
Build → Enable → Accelerate → Transform. The four load-bearing tiers of the enterprise commercial technology stack — sequenced so AI capabilities can actually work. The original sequencing framework, in full: tiers, gates, use cases, and decision tool.
Read the framework →Volume I · The Sequencing SeriesOn this site
The Sequencing Thesis
Why enterprises fail at AI on two different planes at once. Introduces both sequencing frameworks — B·E·A·T and the 5Ps — and their interlock. Includes an embedded 30-second readiness diagnostic.
Read Volume I →Featured · Capability SequencingOn this site
The 5Ps of Outcomes-Driven AI Transformation
POC → Pilot → Product → Platform → Performance. Four stages get you to capability; the fifth is where compounding advantage lives. The full illustrated framework.
Read the framework →Framework · LinkedInJun 19, 2026 · 7 min
The New 4Ps of AI Product Transformation
The product operating model for the AI era, mapped from the classic marketing 4Ps: POC → Pilot → Product → Platform. Why most AI never leaves the demo.
Read on LinkedIn →Essay · MediumApr 22, 2026 · 11 min
The Pharma Commercial Technology Sequencing Problem
Why programs fail on sequence, not platform — and why AI makes the order you build in impossible to ignore. The full B·E·A·T thesis.
Read on Medium →Framework · LinkedInMay 12, 2026 · 8 min
Introducing B·E·A·T
Where the framework started — the original introduction of B·E·A·T as a sequencing model for pharma commercial AI. Build, Enable, Accelerate, Transform.
Read on LinkedIn →Essay · LinkedInMay 22, 2026 · 6 min
Everyone Is Running to Catch the AI Train — But Who’s Driving the Bus?
Plenty of urgency to board the AI train. Far less clarity on who’s steering. A reflection on choosing direction over motion in enterprise AI.
Read on LinkedIn →Essay · LinkedInJun 2, 2026 · 6 min
The Tools Keep Changing. What I Learned in My First Job Hasn’t.
Two decades in, the tools are unrecognizable — the fundamentals of building things people actually use are not. On what endures beneath the hype.
Read on LinkedIn →Tool · This site
The B·E·A·T Decision Tool
Score where your organization sits and get a sequence recommendation in two minutes — interactive tool, tier maps, and 34 verified references.
Explore the framework →Frameworks & articles © 2026 Saurav Gupta. Personal perspective — the views expressed are my own and do not represent any employer, client, or affiliated organization.
Citations & Sources
34 Verified References
All statistics and research claims in this framework are grounded in the following publicly available sources. Every reference was verified and confirmed findable as of April 2026. Numbers in brackets throughout the document correspond to these references.
Note on sourcing: This framework draws on research across Gartner, McKinsey, IQVIA, Accenture, URAC, Pharmaceutical Commerce, Optum, and industry publications. Sources include major consulting research, government and standards body reports, peer-reviewed case studies, and verified industry publications. All URLs were confirmed active at time of publication.
[1]
Gartner (2025)
“Lack of AI-Ready Data Puts AI Projects at Risk”
Gartner predicts 60% of AI projects lacking AI-ready data will be abandoned by 2026. Survey of 248 data management leaders, Q3 2024.
https://www.gartner.com/en/newsroom/press-releases/2025-02-26-lack-of-ai-ready-data-puts-ai-projects-at-risk
[2]
Gartner (2024)
“Gartner Predicts 30% of Generative AI Projects Will Be Abandoned After Proof of Concept By End of 2025”
At least 30% of GenAI projects abandoned after proof of concept due to poor data quality, inadequate risk controls, or unclear business value.
https://www.gartner.com/en/newsroom/press-releases/2024-07-29-gartner-predicts-30-percent-of-generative-ai-projects-will-be-abandoned-after-proof-of-concept-by-end-of-2025
[3]
McKinsey & Company (2023)
“The State of AI in 2023: Generative AI’s Breakout Year”
Pharma and medical products among highest-impact gen AI industries — potential value up to 5% of global industry revenue. Survey of 1,684 participants, April 2023.
https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai-in-2023-generative-ais-breakout-year
[4]
McKinsey & Company (2023)
“The Economic Potential of Generative AI: The Next Productivity Frontier”
Gen AI expected to deliver 3–5% productivity value of global pharma/medical products revenue. Four functions account for 75% of total annual value.
https://www.mckinsey.com/capabilities/mckinsey-digital/our-insights/the-economic-potential-of-generative-ai-the-next-productivity-frontier
[5]
McKinsey & Company (2022)
“Demystifying the Omnichannel Commercial Model for Pharma Companies in Asia”
Well-executed omnichannel commercial transformation creates 5–10% revenue uplift, 10–20% marketing efficiency gains, 3–5% increase in prescribers.
https://www.mckinsey.com/jp/en/our-insights/demystifying-the-omnichannel-commercial-model-for-pharma-companies-in-asia
[6]
McKinsey & Company (2023)
“How Medtechs Can Meet Industry Demand for Omnichannel Engagement”
Companies with the highest omnichannel maturity had more than 2× the revenue growth of average maturity peers (2021–2022). Survey of 1,900+ medtech leaders.
https://www.mckinsey.com/industries/life-sciences/our-insights/how-medtechs-can-meet-industry-demand-for-omnichannel-engagement
[7]
IQVIA Institute for Human Data Science (2023)
“The Global Use of Medicines 2023: Outlook to 2027”
Global pharmaceutical market forecast to reach ~$1.9 trillion by 2027. Annual report on global medicine spending and usage trends.
https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2023
[8]
IQVIA (2023)
“AI in Life Sciences Commercialization”
Survey of commercial leaders on AI adoption patterns, data readiness, and commercial AI deployment barriers in life sciences.
https://www.iqvia.com/library/white-papers/ai-in-life-sciences-commercialization
[9]
Accenture (2023)
“Biopharma Technology Trends 2023”
Nearly 40% of life sciences work hours will be impacted by AI — augmented or automated. Four tech trends reshaping biopharma commercialization.
https://www.accenture.com/us-en/insights/life-sciences/biopharma-technology-trends-2023
[10]
Accenture Life Sciences (2023)
“Reinventing Commercialization: Shaping a More Modern & Sustainable Model”
Five-year study of 15 biopharma companies: top 8 performers averaged $1B extra annual revenue vs. analyst forecast (2018–2022). Via Fierce Pharma.
https://www.fiercepharma.com/pharma/investment-and-innovation-are-critical-maximizing-commercial-performance-report
[11]
McKinsey & Company (2022)
“AI Ushers In Next-Gen Prior Authorization in Healthcare”
Physicians spend an average of 13 hours/week on PA-related processes. 93% report care delays; 88% report high administrative burden.
https://www.mckinsey.com/industries/healthcare/our-insights/ai-ushers-in-next-gen-prior-authorization-in-healthcare
[12]
URAC (2023)
“2022 Specialty Pharmacy Performance Measurement: Aggregate Summary Report”
Average total time to fill specialty pharmacy prescriptions: 5.78 business days. New prescriptions take ~3× longer than refills. Based on 343 specialty pharmacies.
https://www.urac.org/wp-content/uploads/2023/02/2022_URAC_Specialty-Pharmacy_Aggregate-Summary-Report.pdf
[13]
VMS BioMarketing / MM+M (2024)
“Hub Services, Patient Engagement, and Specialty Pharmacy: One Patient Support Ecosystem”
Case study: patient engagement provider reduced hub receipt-to-dispense time from 18-day historical average to 9.8 days. 15%+ improvement in 90-day persistence rate.
https://www.mmm-online.com/home/channel/sponsored/vms-biomarketing-one-patient-support-ecosystem/
[14]
Pharmaceutical Commerce (2023)
“Next Best Action for Data Analytics”
Pharma manufacturer spending on data analytics forecast to grow 27% CAGR, reaching $1.2B by 2030. NBA systems represent a new era of data science in drug commercialization.
https://www.pharmaceuticalcommerce.com/view/-next-best-action-for-data-analytics
[15]
IQVIA (2023)
“Mastering the Art of Next Best Action: A Beginner’s Guide for the Pharmaceutical Industry”
Over 80% of pharmaceutical companies expected to implement or have a Next Best Action (NBA) program by end of 2023.
https://www.iqvia.com/locations/united-states/blogs/2023/04/mastering-the-art-of-next-best-action
[16]
Naviant (WPS Health Solutions case study) (2023)
“How AI Technology Reduces Prior Authorization Processing Time by 30.27%”
Real-world deployment: AI-powered PA system achieved 30.27% reduction in PA processing time, handling 170,000 documents annually.
https://naviant.com/blog/ai-prior-authorizations/
[17]
Grand View Research (citing Cardinal Health, 2022) (2024)
“Pharma Hub and Patient Access Support Service Market Report 2033”
More than 90% of physicians face patient care delays due to prior authorization; 37% abandon PA requests entirely.
https://www.grandviewresearch.com/industry-analysis/pharma-hub-patient-access-support-service-market-report
[18]
Optum Rx (2024)
“Automating the Prior Authorization Process”
Cleveland Clinic pilot: 88% reduction in PA appeals, 68% reduction in denials due to missing information. Physician abandonment rate fell from 31% to 25%.
https://business.optum.com/en/insights/automating-prior-authorization-process.html
[19]
McKinsey & Company (2025)
“The State of AI: How Organizations Are Rewiring to Capture Value”
78% of organizations now use AI in at least one business function; only ~1% of executives describe gen AI rollouts as ‘mature.’ Scaling gap remains defining challenge.
https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai-how-organizations-are-rewiring-to-capture-value
[20]
Phil.us (2023)
“Hubs, Digital Pharmacies, and Specialty Pharmacies: What Pharma Access Teams Should Know”
Specialty drugs accounted for 55% of net pharmaceutical spending in 2022 (up from 28% in 2011). An estimated 3 out of 4 patients fail to fill a new specialty brand prescription due to payer controls.
https://phil.us/hubs-digital-pharmacies-and-specialty-pharmacies-what-pharma-access-teams/
[21]
Pharmaceutical Executive (2023)
“22nd Annual Industry Audit: The Pharma Value Picture”
The average SG&A-to-sales ratio for top pharma companies in 2022 was 40.5%. Large pharma companies routinely spend 25–40% of revenue on SG&A, which includes all commercial operations and technology investment.
https://www.pharmexec.com/view/22nd-annual-industry-audit-pharma-value-picture
[22]
SS&C Blue Prism (2023)
“Intelligent Automation for Provider Prior Authorization”
Healthcare providers implementing authorization automation reduce processing times for high-risk authorizations from 8–10 days to 4–5 days. With fully automated solutions, processing targets of 24–48 hours become achievable.
https://www.blueprism.com/resources/blog/healthcare-prior-authorization-automation/
[23]
Pharmaceutical Executive (2025)
“Pharma’s Next Commercial Frontier: Orchestrating Data, AI, and CRM for True Customer Centricity”
In one global program, consolidating 12 regional CRMs into a single engagement graph reduced duplicate HCP records by nearly half and improved launch readiness by more than 25%. Teams aligned on a unified HCP identity achieved real-time field productivity visibility. Also cites: 74% of healthcare staff report duplicated efforts due to siloed data sources (BMC Health Services Research).
https://www.pharmexec.com/view/next-commercial-frontier-orchestrating-data-ai-crm-true-customer-centricity
[24]
Veeva Systems (2024)
“The State of Data, Analytics, and AI in Commercial Biopharma”
Survey of 116 senior life sciences leaders. 89% of biopharma AI pilots fail to scale. 96% of leaders say their data is not AI-ready for fully scaling pilots. 67% have abandoned an AI initiative due to bad data foundation. 73% report significant data quality issues. 72% of companies spend up to 100 days/year reconciling HCP data. Fragmented data linked to 2-month launch delays and 15% lower early script volume in documented case study.
https://www.veeva.com/resources/the-state-of-data-analytics-and-ai-in-commercial-biopharma/
[25]
BCG (Boston Consulting Group) (2023)
“Scaling AI Pays Off, No Matter the Investment”
Based on BCG’s Digital Acceleration Index survey of 2,700 business leaders across 21 countries. Only 11% of companies have released significant value from AI; the majority have failed to scale AI beyond pilots. AI leaders invest an average of 4% of revenues in AI-specific initiatives vs. 2.7% for laggards.
https://www.bcg.com/publications/2023/scaling-ai-pays-off
[26]
BCG (Boston Consulting Group) (2022)
“Mind the Tech Gap” — BCG Digital Transformation Survey
Survey of nearly 2,700 executives across 13 countries. 94% of companies want substantial digital transformation impact, but 70% of digital transformations fail to achieve their objectives, often with profoundly damaging consequences. 60% plan to increase digital spending despite economic headwinds.
https://www.bcg.com/press/1december2022-bcg-x-new-hybrid-of-consulting-and-tech-build-design-capabilities
[27]
BCG (Boston Consulting Group) (2020)
“Flipping the Odds of Digital Transformation Success”
Only 30% of digital transformations succeed in achieving their objectives and creating sustainable change. The 44% in the “worry zone” create some value but miss targets. The 26% in the “woe zone” create less than 50% of target value. Successful transformations created 66% more value and improved corporate capabilities by 82% vs. failures.
https://www.bcg.com/publications/2020/increasing-odds-of-success-in-digital-transformation
[28]
ZS Associates — ZAIDYN® Orchestration Engine (2024)
“NBA-Driven Customer Engagement with ZAIDYN Orchestration Engine”
ZS’s ZAIDYN platform drives personalization at scale, leading to a 15–40% increase in customer engagement through omnichannel Next Best Action. The platform integrates CRM, MDM, claims, and digital data into a unified decisioning engine. Requires a clean, mastered HCP identity layer as the foundation; fragmented identity data produces recommendations field teams cannot trust.
https://www.zs.com/insights/omnichannel-nba-personalization-zaidyn-orchestration-engine
[29]
Databricks (2024)
“Elevating Customer Experience with AI-Enabled Omnichannel Next Best Action”
AI-enabled omnichannel NBA improves HCP engagement by 30–40% and increases sales by 4–10%. Requires data integration across customer profiles, sales data, and engagement history. An HCP receives an average of nine solicitations daily; NBA’s impact depends entirely on data quality and identity resolution underpinning the recommendation engine.
https://www.databricks.com/blog/elevating-customer-experience-ai-enabled-omnichannel-next-best-action
[30]
ZS Associates — Life Sciences Customer Engagement (2025)
“What Every Life Sciences Leader Needs to Know About Customer Engagement in 2025”
SG&A expenses in life sciences range from 25–40% of revenue; marketing and sales make up about 85% of that. Pharma is preparing for 400+ new product launches over the next five years. Among top-20 pharma companies, “digital pioneers” who built centralized data infrastructure first have achieved the highest omnichannel maturity. The key barrier to true omnichannel: no single owner of the customer identity. Without a central, unified HCP view, commercial teams remain fragmented.
https://www.zs.com/insights/life-sciences-leaders-customer-engagement-2025
[31]
Salesforce (2024)
“Salesforce Life Sciences Cloud & Unified Data Platform for Life Sciences”
Life Sciences Cloud uses a Unified Data Platform (Data Cloud + MuleSoft) to create harmonized HCP and patient profiles from CRM, claims, prescriptions, EHRs, and engagement history. The platform illustrates the Enable tier’s architecture: unified identity, consent, and cross-channel signal are prerequisites before AI-driven next best action and agentic engagement can function. 88% of healthcare and life sciences organizations have not yet realized their digital transformation goals. Pharma companies using unified CRM data report reduced redundant outreach and improved AI-powered recommendations.
https://www.salesforce.com/news/stories/life-sciences-cloud-ai-availability/
[32]
EY (Ernst & Young) (2023)
“How Electronic Prior Authorization Can Help Health Care”
EY research documents that reducing administrative overhead and improving payer-provider collaboration via PA automation requires an end-to-end approach with digital workflows and real-time EHR connectivity. Current PA processes take up valuable time and resources that could otherwise be used to save costs and provide patients more timely care. A next-generation PA experience requires rapid shifts in organizational priorities, a digital operating model, and advanced technology capabilities — none of which function without integrated claims data and unified patient identity as the foundation.
https://www.ey.com/en_us/insights/health/how-electronic-prior-authorization-can-help-health-care
[33]
CoverMyMeds / McKesson (2023)
“Benefits of Outsourcing Field Reimbursement Services” & Patient Support Program Data
PA delays range from days to weeks without automation. CoverMyMeds e-enrollment reduces time to therapy by up to 4 days (study across 3 drugs, 33,000+ enrollments over 2 years). When Reimbursement Specialists are deployed with hub technology integration, hub programs see an average 8% increase in patient enrollment following a PA denial. Siloed hub and patient support services mean field teams often lack visibility into patient journey data — the exact problem the Build tier is designed to solve. PA and benefit verification are “table stakes” for the specialty patient support field.
https://insights.covermymeds.com/healthcare-industry/pharma/benefits-of-outsourcing-field-reimbursement-services-with-covermymeds
[34]
MIT Sloan Management Review (2023)
“Why AI Projects Fail” — AI Success Factors in Enterprise
MIT Sloan research on enterprise AI deployments confirms that AI success depends on data maturity and process integration, not model sophistication. Organizations that invest in data infrastructure and cross-functional process alignment before deploying AI models achieve materially better outcomes. Agentic and autonomous AI capabilities in particular require production-stable data foundations — otherwise automation amplifies existing errors at scale rather than reducing them. The technology is rarely the limiting factor; the data and process architecture underneath it is.
https://sloanreview.mit.edu/article/why-ai-projects-fail/
SG
Saurav Gupta — Personal Perspective & Disclaimer
The views expressed in this framework are those of Saurav Gupta personally and do not represent the views, positions, strategies, or endorsement of any employer, client, or affiliated organization. The B·E·A·T Framework is original practitioner work based on industry experience and publicly available research. Customer personas are illustrative composites. © 2026 Saurav Gupta. Reproduction permitted with attribution for non-commercial professional discussion.